Why did VERAXA Biotech (NASDAQ:VRXA) start cell line development for BiTAC-TCE?

VERAXA Biotech (NASDAQ:VRXA) initiated cell line development to support manufacturing readiness for its lead BiTAC T-cell engager program. This step helps prepare for IND and CTA filings.

What is ATUM’s role in the VERAXA Biotech (NASDAQ:VRXA) program?

ATUM is providing Leap-In Transposase technology to help generate stable clonal cell lines. This supports consistent production of VERAXA’s BiTAC-TCE candidate.

What is a BiTAC-TCE for VERAXA Biotech (NASDAQ:VRXA)?

A BiTAC-TCE is a T-cell engager designed to direct immune cells to target specific disease-related cells. VERAXA Biotech (NASDAQ:VRXA) is developing it as a lead therapeutic candidate.

What does IND/CTA-enabling mean for VERAXA Biotech (NASDAQ:VRXA)?

IND/CTA-enabling activities refer to the preclinical steps required before regulatory approval for human clinical trials. VERAXA Biotech (NASDAQ:VRXA) said this work supports future clinical development.

What is the significance of cell line development for VERAXA Biotech (NASDAQ:VRXA)?

Cell line development ensures stable production of therapeutic proteins for clinical testing. For VERAXA Biotech (NASDAQ:VRXA), it is a key step toward manufacturing readiness for its lead program.

Image for illustrative purposes only. Not a real photo.

VERAXA starts cell line work for BiTAC T-cell engager

Written by Heidi Cuthbert Published Jul 2, 2026, 11:24 AM

VERAXA Biotech (NASDAQ:VRXA) initiated cell line development for its lead BiTAC-TCE program.
The company is working with ATUM to use Leap-In Transposase technology for stable clonal cell lines.
The step supports IND/CTA-enabling activities for future clinical development.

VERAXA Biotech (NASDAQ:VRXA) said it has begun cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) candidate.

The company is partnering with ATUM to apply its Leap-In Transposase technology in developing stable clonal cell lines.

VERAXA said the process is a key step toward IND and CTA-enabling activities required before human clinical trials.

The cell line development is intended to support future manufacturing and clinical production of the BiTAC-TCE program.

BiTAC-TCE programs are designed to engage T-cells to target disease-related cells, and stable cell line development is a standard early-stage manufacturing milestone.

VERAXA said the collaboration supports advancement of its most developed BiTAC-TCE candidate toward clinical readiness.